Glycobond
Link├╢ping
About Glycobond
Glycobond develops and produces proprietary carbohydrate-binding reagents for use in diagnostics. Glycobond has developed HepaCheC™, an ELISA-based assay that detects aberrant and cancer-specific glycosylation on alpha-1 acid glycoprotein (AGP), an acute phase plasma protein produced mainly in the liver. The protein is secreted into the blood stream why analysis can be performed on a simple blood sample. The method is based on a patented fucose-binding protein, Mono-F, and has shown very promising results in longitudinal analyses of serum samples from patients at risk of developing HCC.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $59.5K
- Last round: Grant (Dec 2017)
- Website: glycobond.com
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/glycobond-2212572 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.